Literature DB >> 6526737

Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines.

S Kunimoto, K Miura, K Umezawa, C Z Xu, T Masuda, T Takeuchi, H Umezawa.   

Abstract

Cellular uptake and cytostatic activity of 4'-O-tetrahydropyranyladriamycin (THP) in various sublines resistant to anthracycline antibiotics of mouse lymphoblastoma L5178Y, Chinese hamster ovary (CHO) and mouse leukemia P388 cells were studied. All the sublines resistant to adriamycin (ADR) showed slightly decreased uptake of THP as compared with each sensitive lines, but THP was still taken up much more quickly than ADR by each of the ADR-resistant cell lines. Efflux of both anthracycline glycosides from the ADR-resistant P388 cells was faster than that from the ADR-sensitive P388 cells. The percentage of THP retained at equilibrium was higher than that of ADR in both ADR-resistant and -sensitive P388 cells. Cytotoxicity of THP to ADR-resistant cell lines was considerably lower compared with that for each of the sensitive lines but THP inhibited growth of ADR-resistant tumor cells at a concentration about 10 times lower than that for ADR. Thus THP was taken up more quickly, effluxed more slowly than ADR from the ADR-resistant cells, and showed stronger cytostatic activity than ADR on the cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6526737     DOI: 10.7164/antibiotics.37.1697

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.

Authors:  Shuier Zheng; Shuhui Zhou; Guanglei Qiao; Qingcheng Yang; Zhichang Zhang; Feng Lin; Daliu Min; Lina Tang; Hongtao Li; Yuanjue Sun; Hui Zhao; Zan Shen; Yang Yao
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.

Authors:  R Ohno; K Kimura; I Amaki; M Hirano; A Hoshino; Y Ikeda; I Kimura; M Kobayashi; K Konno; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin.

Authors:  Yaran Wu; Zhenhong Ni; Xiaojing Yan; Xufang Dai; Changjiang Hu; Yingru Zheng; Fengtian He; Jiqin Lian
Journal:  Autophagy       Date:  2016-04-20       Impact factor: 16.016

4.  Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.

Authors:  Shui-er Zheng; Sang Xiong; Feng Lin; Guang-lei Qiao; Tao Feng; Zan Shen; Da-liu Min; Chun-ling Zhang; Yang Yao
Journal:  Acta Pharmacol Sin       Date:  2012-05-14       Impact factor: 6.150

5.  Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin.

Authors:  Kenji Tsukigawa; Long Liao; Hideaki Nakamura; Jun Fang; Khaled Greish; Masaki Otagiri; Hiroshi Maeda
Journal:  Cancer Sci       Date:  2015-02-03       Impact factor: 6.716

6.  Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro.

Authors:  H Suzuki; A Tomida; T Nishimura
Journal:  Jpn J Cancer Res       Date:  1990-03

7.  Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin.

Authors:  Kenji Tsukigawa; Shuhei Imoto; Keishi Yamasaki; Koji Nishi; Toshihiko Tsutsumi; Shoko Yokoyama; Yu Ishima; Masaki Otagiri
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.